Bolt Biotherapeutics
900 Chesapeake Drive
Redwood City
CA
94063
United States
Tel: (650) 665-9295
Website: https://www.boltbio.com/
Email: careers@boltbio.com
About Bolt Biotherapeutics
Bolt Biotherapeutics was founded in 2015 by Dr. Edgar G. Engleman of Stanford University to expand upon his pioneering work in cancer immunotherapeutics and myeloid biology. Bolt is based in the San Francisco Bay area.
Bolt’s highly qualified management team includes experienced leaders in immuno-oncology drug discovery, development and commercialization. Our goal is to leverage our myeloid biology expertise to discover, develop and commercialize transformative treatments to address key unmet medical needs for patients with cancer.
90 articles about Bolt Biotherapeutics
-
Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors
1/6/2022
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that the first patient has been dosed in a new combination arm of the ongoing multi-center, multi-dose Phase 1/2 clinical trial of BDC-1001.
-
Bolt Biotherapeutics Appoints Nicole Onetto, M.D., to Board of Directors
12/16/2021
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced the appointment of Nicole Onetto, M.D., to its Board of Directors effective Dec. 14, 2021.
-
Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021
12/6/2021
Bolt Biotherapeutics, Inc. announced the presentation of interim clinical data from the company’s ongoing Phase 1/2 study of BDC-1001, the company’s lead immune-stimulating antibody conjugate in a poster session at the European Society for Medical Oncology Immuno-Oncology Congress 2021, being held virtually from Dec. 6-11, 2021.
-
Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021
12/2/2021
Bolt Biotherapeutics, Inc. announced that the company will be presenting interim clinical data in a virtual poster on BDC-1001, starting on December 6, 2021 in conjunction with the European Society for Medical Oncology Immuno-Oncology Congress 2021 taking place on December 8 - 11, 2021.
-
Bolt Biotherapeutics Announces Changes to its Board of Directors
11/19/2021
Bolt Biotherapeutics (Nasdaq: BOLT), today announced the appointments of Brian O’Callaghan and Frank D. Lee to the Board of Directors.
-
Bolt Biotherapeutics Presents New Preclinical Data on Three Pipeline Programs at Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/12/2021
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), today announced the company will be presenting posters with new data from three of its pipeline programs on Saturday, Nov. 13, at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
-
Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights
11/9/2021
Bolt Biotherapeutics, Inc. a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, reported financial results for the third quarter ended September 30, 2021 and provided an update on recent business highlights.
-
Bolt Biotherapeutics to Present at Stifel 2021 Virtual Healthcare Conference
11/8/2021
Bolt Biotherapeutics (Nasdaq: BOLT), today announced that Randall C. Schatzman, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 1:00 p.m. PT (4:00 p.m. ET).
-
Bolt Biotherapeutics to Present Updates on Three Pipeline Programs at the 2021 Society for Immunotherapy of Cancer Annual Meeting (SITC)
10/1/2021
Bolt Biotherapeutics, Inc. announced that it will be presenting three abstracts at the 2021 Society for Immunotherapy of Cancer’s 36th Annual Meeting, which is being held from Nov. 10-14, both virtually and in person in Washington, D.C.
-
It's a New Hybrid World for Biopharma
9/20/2021
One constant throughout the conversation is that the industry is at a different stage of adapting to the “new normal.” -
In a recent multinational survey, healthcare providers expressed the belief that immunotherapy will improve outcomes for patients with earlier-stage cancers.
-
Bolt Biotherapeutics was anything but quiet this summer.
-
Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo® for Treatment of HER2-Expressing Solid Tumors
9/8/2021
Bolt Biotherapeutics, Inc. today announced that it has entered into a clinical collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to investigate Bolt Biotherapeutics’ BDC-1001 in combination with Bristol Myers Squibb’s PD-1 checkpoint inhibitor Opdivo® (nivolumab).
-
Bolt Biotherapeutics to Participate in Upcoming September 2021 Investor Conferences
9/2/2021
Bolt Biotherapeutics announced that management will present a corporate update and conduct meetings with the investment community at four upcoming virtual investor conferences in September:
-
Innovent and Bolt Biotherapeutics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs
8/26/2021
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), and Bolt Biotherapeutics, Inc. ("Bolt") (Nasdaq: BOLT), today announced a drug research and development collaboration to develop three new anti-cancer therapeutic immune-stimulating antibody conjugate (ISAC) candidates.
-
Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs
8/26/2021
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), and Innovent Biologics, Inc. (HKEX: 01801), today announced a drug research and development collaboration to develop three new anti-cancer therapeutic immune-stimulating antibody conjugate (ISAC) candidates.
-
Bolt Biotherapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights
8/12/2021
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today reported financial results for the second quarter ended June 30, 2021 and provided an update on recent business highlights.
-
Bolt Biotherapeutics Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001 at ASCO 2021
6/4/2021
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that a poster presentation discussing preliminary data from the Phase 1/2 clinical trial of BDC-1001,
-
Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration
6/2/2021
Genmab A/S and Bolt Biotherapeutics, Inc. announced that the companies have entered into an oncology research and development collaboration.
-
Bolt Biotherapeutics Reports First Quarter 2021 Financial Results and Provides Business Highlights
5/13/2021
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today reported financial results for the first quarter ended March 31, 2021 and provided an update on recent business highlights.